The advantage of genomic monitoring over cytogenetics for clinical assessment of leukemia is illustrated by a case of pediatric acute lymphoblastic leukemia in which a lesion underlying lethal end-stage myeloid disease could be detected by whole-genome sequencing years before the risk manifested cytogenetically.
References
Farber, S. & Diamond, L. K. N. Engl. J. Med. 238, 787–793 (1948).
Bolouri, H. et al. Nat. Med. 24, 103–112 (2018).
Rowley, J. D. Nature 243, 290–293 (1973).
Rowley, J. D. Proc. Natl Acad. Sci. USA 72, 152–156 (1975).
Druker, B. J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Nowell, P. C. Science 194, 23–28 (1976).
McNeer, N. A. et al. Leukemia 33, 1934–1943 (2019).
Coorens, T. H. H. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00604-0 (2023).
van der Sluis, I. M. et al. N. Engl. J. Med. 388, 1572–1581 (2023).
Dobzhansky, T. Am. Biol. Teach. 35, 125–129 (1973).
Wong, T. N. et al. Nature 518, 552–555 (2015).
Alexander, T. B. et al. Nature 562, 373–379 (2018).
Lamble, A. J. et al. Blood 138, 256–256 (2021).
Pulsipher, M. A. et al. Blood 140, 2556–2572 (2022).
Duffner, U. et al. Leukemia 30, 1619–1621 (2016).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harmon, L.M., Triche, T.J. Evolutionary genomic analysis for ALL. Nat Cancer 4, 1058–1059 (2023). https://doi.org/10.1038/s43018-023-00605-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00605-z
- Springer Nature America, Inc.